Get the Stockscreener App
167.35
4.46%
7.14
Pre-market:
167.55
0.20
+0.12%
Natera Inc stock is traded at $167.35, with a volume of 1.15M.
It is up +4.46% in the last 24 hours and down -0.11% over the past month.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
See More
Previous Close:
$160.21
Open:
$161.54
24h Volume:
1.15M
Relative Volume:
0.92
Market Cap:
$22.97B
Revenue:
$1.96B
Net Income/Loss:
$-253.24M
P/E Ratio:
-87.62
EPS:
-1.91
Net Cash Flow:
$94.06M
1W Performance:
+2.69%
1M Performance:
-0.11%
6M Performance:
+20.65%
1Y Performance:
+32.50%
1-Day Range:
$160.59
$167.91
1-Week Range:
$157.43
$167.91
52-Week Range:
$117.27
$183.00
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
167.35 | 21.99B | 1.96B | -253.24M | 94.06M | -1.91 |
|
TMO
Thermo Fisher Scientific Inc
|
543.32 | 198.23B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
214.99 | 150.61B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
631.19 | 50.71B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
141.64 | 39.32B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
206.63 | 34.74B | 15.70B | 1.24B | 2.01B | 6.9036 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-22-25 | Resumed | Wells Fargo | Equal Weight |
| Mar-13-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-08-24 | Resumed | Craig Hallum | Buy |
| Feb-20-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-05-23 | Initiated | UBS | Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Mar-08-22 | Initiated | Goldman | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Sep-28-20 | Initiated | Morgan Stanley | Overweight |
| Sep-17-20 | Initiated | SVB Leerink | Outperform |
| Jun-10-20 | Resumed | Piper Sandler | Overweight |
| May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-05-18 | Initiated | JP Morgan | Neutral |
| Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
| Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-10-16 | Reiterated | The Benchmark Company | Buy |
| May-23-16 | Reiterated | The Benchmark Company | Buy |
| May-11-16 | Reiterated | The Benchmark Company | Buy |
| Apr-19-16 | Initiated | The Benchmark Company | Buy |
| Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-04-15 | Initiated | Robert W. Baird | Outperform |
| Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-27-15 | Initiated | Piper Jaffray | Overweight |
| Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
Chart based exit strategy for Natera Inc.Volume Spike & Daily Market Momentum Tracking - newser.com
Is Natera Inc. building a consolidation base2025 Stock Rankings & Precise Swing Trade Entry Alerts - newser.com
How institutional ownership impacts Natera Inc. stockJuly 2025 Technicals & Fast Exit Strategy with Risk Control - newser.com
Why Natera Inc. stock remains on buy lists2025 Volume Leaders & Fast Gain Swing Trade Alerts - newser.com
Combining machine learning predictions for Natera Inc.Market Weekly Review & Weekly Chart Analysis and Trade Guides - newser.com
Barclays Keeps Their Buy Rating on Natera (NTRA) - The Globe and Mail
Natera (NTRA): Exploring Valuation as Share Price Pulls Back Despite Strong Growth - simplywall.st
Natera (NTRA): Assessing Valuation Potential as Shares Enter a Quiet Phase - simplywall.st
Is Natera Inc. a candidate for recovery play2025 AllTime Highs & Accurate Trade Setup Notifications - newser.com
Natera Stock (NTRA) Opinions on EXPAND Trial Enrollment and Insider Sales - Quiver Quantitative
Natera CEO Chapman sells $3.7m in stock By Investing.com - Investing.com South Africa
Enrollment Tops 1,600 in Natera’s EXPAND Trial of Single Gene NIPT - BioSpace
Natera enrolls over 1,600 patients in EXPAND trial for fetal testing - Investing.com Nigeria
Insider Sell: Solomon Moshkevich Sells 3,000 Shares of Natera In - GuruFocus
Natera (NTRA) sec. Rabinowitz sells $221k in shares By Investing.com - Investing.com Australia
Natera CFO Brophy sells $403,673 in shares By Investing.com - Investing.com South Africa
Natera CEO Chapman sells $3.7m in stock - Investing.com India
Natera (NTRA) sec. Rabinowitz sells $221k in shares - Investing.com India
Natera CFO Brophy sells $403,673 in shares - Investing.com India
Natera Inc: president Moshkevich sells $479k in stock By Investing.com - Investing.com South Africa
Natera Inc: president Moshkevich sells $479k in stock - Investing.com
Natera, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
Why Natera’s Stock is Gaining Attention - TipRanks
Natera (NTRA) Achieves Key Enrollment Milestone in EXPAND Trial - GuruFocus
Natera enrolls over 1,600 patients in EXPAND trial for fetal testing By Investing.com - Investing.com South Africa
Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer - BioSpace
Natera’s ctDNA test outperforms standard markers in testicular cancer By Investing.com - Investing.com Nigeria
Natera’s ctDNA test outperforms standard markers in testicular cancer - Investing.com India
Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows - BioSpace
Natera, Inc. (NASDAQ:NTRA) Given Average Rating of "Buy" by Brokerages - MarketBeat
GAMMA Investing LLC Acquires 411 Shares of Natera, Inc. $NTRA - Defense World
Natera's president sells shares worth $117,861 - MSN
Natera’s Signatera test shows strong results for uterine cancer monitoring By Investing.com - Investing.com Canada
Natera’s Signatera test shows strong results for uterine cancer monitoring - Investing.com
SWS Partners Reduces Stake in Natera, Inc. $NTRA - MarketBeat
Natera, Inc. (NTRA) Stock Analysis: Evaluating the 18.92% Upside Potential in Healthcare Diagnostics - DirectorsTalk Interviews
Natera, Inc. (NTRA) Stock Analysis: 18.92% Potential Upside Amid Robust Revenue Growth - DirectorsTalk Interviews
Natera, Inc. $NTRA Shares Acquired by Farther Finance Advisors LLC - MarketBeat
CareDx Asks 3rd Circ. To Rethink $45M False Ad Case - Law360
Natera Inc Stock (NTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.89%
2.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):